Long-Term Outcomes of Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals in Turkey

Objectives: Direct-acting antivirals (DAA) improve clinical outcomes in chronic hepatitis C (CHC).Data about the long-term outcomes of patients with CHC treated with DAAs in Turkey.We aimed to analyze the characteristics and outcomes of patients with CHC who attended the 3-year follow-up visit after completing DAA therapy and to present their implications for clinical management and public health.Materials and Methods: This single-center, single-arm, retrospective study included adult CHC patients treated with DAA ribavirin and attended the year 3 follow-up visit after completing treatment.Data on patient characteristics, laboratory parameters, recurrent/relapsing hepatitis C virus (HCV) infection, cirrhosis, and hepatocellular carcinoma (HCC) were collected from the hospital medical records and descriptively analyzed.Results: Sixty-eight patients (55.9% women), including 15 patients (22.1%) of foreign origin, were included in the study.Forty-six patients (67.6%) had a known route of HCV transmission, and 27 (58.7%)were infected through blood transfusion and/or surgical intervention.Most participants (57.4%) were infected with HCV genotype (GT) 1b: all patients of European origin with GT1b, two-thirds of Syrian participants with GT4, and half of Asians with GT3.Three patients had cirrhosis (4.4%; all compensated) at baseline.No patient developed relapse, reinfection, cirrhosis, decompensation, or HCC.Conclusion: Sustained virologic response, absence of new cases of cirrhosis, decompensation, or HCC during follow-up support the Z Ama: Direkt etkili antiviraller (DAA), kronik hepatit C (KHC) tedavi sonular iyiletirmitir.Trkiye'de DAA'larla tedavi edilen KHC hastalarnn uzun dnem takibine ilikin veriler snrldr.DAA tedavisini tamamladktan sonra 3. yl takibine gelen KHC hastalarnn zelliklerini ve sonularn analiz etmeyi ve bunlarn tedavi ynetimine ve halk salna etkilerini sunmay amaladk.Gere ve Yntemler: Bu tek merkezli, tek kollu, retrospektif almaya DAA ribavirin ile tedavi edilen ve tedavi tamamlandktan sonra 3. yl takibine gelen yetikin KHC hastalar dahil edildi.Hastalarn zellikleri, laboratuvar parametreleri, nks veya yeni gelien hepatit C virs (HCV) enfeksiyonu, siroz ve hepatoseller karsinom (HCC) geliimi verileri hastane tbbi kaytlarndan toplanm ve tanmlayc olarak analiz edilmitir